Novartis CEO: 4 factors can help the industry price and pay for lifesaving cell and gene therapies

Novartis CEO Vas Narasimhan says there is a fundamental challenge with pricing new cell and gene therapies that are potentially curative: how to pay for these therapies and make them available to patients in need.

from Health and Science https://ift.tt/2SbXMxa